- Home
- ALVR vs NTRB Comparison
ALVR vs NTRB Comparison
Compare ALVR & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVR
- NTRB
- Stock Information
- Founded
- ALVR 2013
- NTRB 2016
- Country
- ALVR United States
- NTRB United States
- Employees
- ALVR N/A
- NTRB N/A
- Industry
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- NTRB Industrial Specialties
- Sector
- ALVR Health Care
- NTRB Health Care
- Exchange
- ALVR Nasdaq
- NTRB Nasdaq
- Market Cap
- ALVR 87.7M
- NTRB 77.9M
- IPO Year
- ALVR 2020
- NTRB N/A
- Fundamental
- Price
- ALVR $0.57
- NTRB $4.94
- Analyst Decision
- ALVR Sell
- NTRB
- Analyst Count
- ALVR 5
- NTRB 0
- Target Price
- ALVR $1.00
- NTRB N/A
- AVG Volume (30 Days)
- ALVR 593.0K
- NTRB 17.4K
- Earning Date
- ALVR 11-12-2024
- NTRB 12-11-2024
- Dividend Yield
- ALVR N/A
- NTRB N/A
- EPS Growth
- ALVR N/A
- NTRB N/A
- EPS
- ALVR N/A
- NTRB N/A
- Revenue
- ALVR N/A
- NTRB $1,803,816.00
- Revenue This Year
- ALVR N/A
- NTRB N/A
- Revenue Next Year
- ALVR N/A
- NTRB N/A
- P/E Ratio
- ALVR N/A
- NTRB N/A
- Revenue Growth
- ALVR N/A
- NTRB N/A
- 52 Week Low
- ALVR $0.52
- NTRB $2.22
- 52 Week High
- ALVR $2.49
- NTRB $9.60
- Technical
- Relative Strength Index (RSI)
- ALVR 37.63
- NTRB 40.08
- Support Level
- ALVR $0.52
- NTRB $4.64
- Resistance Level
- ALVR $0.64
- NTRB $5.12
- Average True Range (ATR)
- ALVR 0.10
- NTRB 0.40
- MACD
- ALVR -0.03
- NTRB -0.04
- Stochastic Oscillator
- ALVR 10.28
- NTRB 23.48
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.